

Laser Trabeculoplasty Perceptions and Practice Patterns of Canadian Ophthalmologists

Elizabeth Y Lee¹, Forough Farrokhhyar², Enitan Sogbesan³

ABSTRACT

Aim: To describe the current practice patterns and perceptions of Canadian ophthalmologists using laser trabeculoplasty (LTP).

Materials and methods: A cross-sectional survey of 124 members of the Canadian Ophthalmological Society (COS) who perform LTP was conducted. Descriptive statistics and Chi-square comparative analyses were performed on anonymous self-reported survey data.

Results: Of the 124 respondents, 34 (27.4%) completed a glaucoma fellowship. Use of selective laser trabeculoplasty (SLT) (94.4%) was preferred over argon laser trabeculoplasty (ALT) (5.6%). The most frequently cited reasons for SLT preference was less damage to trabecular meshwork (30.7%), availability (16.2%), and repeatability (16.2%). In all, 47.6% of the respondents performed LTP concurrently with medical treatment, 33.9% used it after medical treatment, and 17.7% used it as first-line treatment. Majority (87.1%) of the respondents believed that SLT is effective when repeated. In suitable patients, 41.9% of the respondents stated on average they repeat SLT once, 26.6% twice, and 19.4% greater than 2 times, respectively. Of those who repeat SLT on patients, 80.7% found repeat SLT treatments have good outcomes for patients. In all, 105 (84.7%) ophthalmologists responded they would benefit from an LTP practice guideline. Significantly more ophthalmologists without glaucoma fellowships perceived they would benefit from a practice guideline (p value <0.001).

Conclusion: This survey provides valuable practical information on how LTP is used in the treatment of glaucoma in Canada.

Clinical significance: The findings may serve as a baseline survey to trend future practices.

Keywords: Argon laser trabeculoplasty, Glaucoma, Glaucoma treatment, Laser therapy, Practice pattern, Selective laser trabeculoplasty.

Journal of Current Glaucoma Practice (2020): 10.5005/jp-journals-10078-1283

Glaucoma is the leading cause of irreversible blindness worldwide.^{1,2} Recent studies have estimated glaucoma to affect 79.6 million³ and 111.8 million⁴ people by 2020 and 2040, respectively. It is associated with irreversible visual field defects caused by chronic, progressive optic neuropathy. Vision loss can be delayed or prevented through early treatment initiation. There are several treatment methods for glaucoma, including medical therapy, laser therapy, and incisional surgeries. All these treatments aim to lower intraocular pressure (IOP), which delays the progression of optic neuropathy.

Laser trabeculoplasty (LTP) is a widely used glaucoma therapy. Argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) are the two most commonly used LTPs in the treatment of open angle glaucoma (OAG). Both laser treatments work by increasing aqueous outflow and decreasing IOP. SLT selectively targets pigmented cells of the trabecular meshwork using a frequency doubled 532 nm Nd:YAG laser,^{5,6} whereas ALT uses an argon green laser of smaller size to target the trabecular meshwork.^{7,8}

Compared to its predecessor, ALT, SLT uses less energy and does not cause coagulative damage to the trabecular meshwork.⁵ For this reason, SLT has been suggested to have successful repeatability. However, in decreasing IOP, both SLT and ALT have been shown to be similar in efficacy.^{9–16} Many studies^{12,14,17–23} have explored how SLT compares to ALT, where it fits in the glaucoma treatment algorithm and the most effective way to administer SLT. However, physician practice patterns and perceptions have not been reported in Canada. This study aims to investigate Canadian ophthalmologists' LTP practice patterns, with an emphasis on SLT.

MATERIALS AND METHODS

An anonymous survey with 26 item electronic was distributed to members of the Canadian Ophthalmological Society (COS) including the Canadian Glaucoma Society. The questionnaire

^{1,3}Department of Ophthalmology, McMaster University, Hamilton, Ontario, Canada

²Department of Surgery, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; Department of Health, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada

Corresponding Author: Elizabeth Y Lee, Department of Ophthalmology, McMaster University, Hamilton, Ontario, Canada, Phone: +613-484-7425, e-mail: elizabeth.lee@medportal.ca

How to cite this article: Lee EY, Farrokhhyar F, Sogbesan E. Laser Trabeculoplasty Perceptions and Practice Patterns of Canadian Ophthalmologists. *J Curr Glaucoma Pract* 2020;14(3):81–86.

Source of support: Nil

Conflict of interest: None

was validated for content, clarity, and comprehensiveness by three glaucoma specialists. Treatment indications, algorithm and techniques, and questions specific to SLT were investigated. Respondents who did not use LTP in their practice were excluded. The initial invitation, with one follow-up reminder e-mail 3 weeks later, was sent in the Spring of 2018. The survey data included multiple-choice and free-text questions. Data were entered in a spreadsheet. Descriptive statistics was performed. The frequencies and relative frequencies are reported for each question. Chi-square test with continuity correction or Fisher's exact test were used for group comparison. A p value of 0.05 was considered for statistical significance, and SPSS software v.24 (Armonk, NY: IBM Corp) was used for data analysis. For comparisons, variable for length of practice was dichotomized to less than 15 years and greater than or equal to 15 years of practice.

RESULTS

A total of 124 responses were included in the analysis. It is unknown how many COS members perform LTP. The response rate was estimated to be 33.3% as 34 of the 94 glaucoma subspecialty members responded. Of the respondents, 71.8% identified as having a comprehensive practice, 25.8% glaucoma practice, and 2.4% other subspecialty practice. With regard to length of practice, 30.2% practiced less than 15 years, and 69.8% practiced greater than or equal to 15 years. Majority of the participants practiced out of a private clinic (82.3%).

Laser Trabeculoplasty Practice Patterns

Table 1 summarizes the responses to questions regarding LTP practice patterns. Fifty-nine (47.6%) of the respondents used LTP concurrently with medical treatment, 42 (33.9%) used LTP after medical treatment but before surgery, and 22 (17.7%) used

Table 1: Summary of responses to LTP practice pattern questions

<i>On average how many ALT/SLT do you perform in a month?</i>	124
Less than 5	36 (29.0)
5–14	51 (41.1)
15–24	24 (19.4)
25–34	6 (4.8)
More than 35	7 (5.6)
<i>For which patient population do you perform LTP?</i>	124
Please check all that applies	
Primary open angle glaucoma	124 (100.0)
Pseudoexfoliation glaucoma	114 (91.9)
Pigmentary glaucoma	97 (78.2)
Ocular hypertension	82 (66.1)
Normal tension glaucoma	74 (59.7)
Steroid-induced glaucoma	32 (25.8)
<i>Where does the initial LTP fall the most in your glaucoma treatment algorithm?</i>	124
First-line treatment of glaucoma	22 (17.7)
Concurrently with medical treatment	59 (47.6)
After medical treatment but before surgery	42 (33.9)
After medical treatment and surgery	1 (0.8)
<i>What influences your LTP practice patterns the most?</i>	122
Evidence in literature	50 (40.3)
Teaching during training	19 (15.3)
Past clinical experience	53 (42.7)
Other	2 (1.6)
<i>Did your use of ALT decrease after the introduction of SLT?</i>	124
Yes	90 (72.6)
No	12 (9.7)
Never did ALT	22 (17.7)
<i>Which laser trabeculoplasty do you use more often?</i>	124
Argon laser trabeculoplasty	7 (5.6)
Selective laser trabeculoplasty	117 (94.4)
<i>Would you benefit from a practice guideline for a laser trabeculoplasty?</i>	124
Yes	105 (84.7)
No	19 (15.3)

it as first-line treatment of glaucoma. Figure 1 demonstrates most respondents used LTP for treatment of primary open angle glaucoma (100.0%) and pseudoexfoliation glaucoma (91.9%), whereas only about a quarter did for steroid-induced glaucoma. Past clinical experience (42.7%) and evidence in the literature (40.3%) were perceived by respondents to influence their practice the most. Majority of the respondents used SLT (94.4%) compared to ALT (5.6%). The most frequently cited reasons for SLT preference was less damage to trabecular meshwork (30.7%), availability (16.2%), and repeatability (16.2%). All but one respondent who preferred ALT stated that they only have access to ALT. After the introduction of SLT, 72.6% reported their use of ALT decreased and 17.7% reported they never used ALT to begin with. Majority (84.7%) of the respondents stated they would benefit from a practice guideline for LTP.

Selective Laser Trabeculoplasty Practice Patterns

Table 2 summarizes the responses to questions regarding SLT practice patterns. Main predictors for SLT success included baseline IOP (70.1%) and type of glaucoma (18.5%) (Fig. 2). When performing SLT, 1.6%, 69.9%, and 25.2% of the respondents stated they treat 90-, 180-, 360-degree of the trabecular meshwork, respectively. Of the 86 respondents who primarily performed 180-degree SLT, the main preferred location was inferior trabecular meshwork (71.6%). Approximately half the respondents stated they complete treatment on the other half of the trabecular meshwork in less than a year. After SLT procedure, 40.3% of respondents did not use any anti-inflammatory medications, whereas 37.1% used topical steroids and 21.8% used topical NSAIDs. Eighty-nine (71.8%) of the respondents stated they felt up-to-date on the latest SLT research.

SLT Repeatability

Majority (87.1%) of the respondents believed SLT was repeatable. In suitable patients, 41.9% of the respondents stated on average they repeat SLT once, 26.6% twice, and 19.4% greater than two times. Seventy-four (68.3%) respondents stated they are more likely to repeat SLT on patients who had previous SLT than previous ALT.




Fig. 1: Types of glaucoma respondents treat using laser trabeculoplasty. POAG, primary open angle glaucoma; PXG, pseudoexfoliation glaucoma; PG, pigmentary glaucoma; OHTN, ocular hypertension; NTG, normal tension glaucoma; SIG, steroid-induced glaucoma

Table 2: Summary of responses to questions regarding SLT

<i>What percentage of your total laser trabeculoplasty is SLT?</i>	117
<20%	0 (0.0)
20–39%	0 (0.0)
40–59%	1 (0.9)
60–79%	2 (1.7)
>80%	114 (97.4)
<i>When performing SLT, how much of the trabecular meshwork do you treat (majority of the time)?</i>	123
90	2 (1.6)
180	86 (69.9)
360	31 (25.2)
Other	4 (3.3)
<i>What do you use as the main predictor of success for SLT procedure?</i>	124
Baseline IOP	88 (71)
Glaucoma type	23 (18.5)
Previous LTP	8 (6.5)
Demographics	2 (1.6)
Angle appearance	3 (2.4)
<i>Which anti-inflammatory medication do you use post-SLT?</i>	124
Steroids	46 (37.1)
NSAID	27 (21.8)
Both	1 (0.8)
None	50 (40.3)
<i>Do you consider yourself up-to-date on latest research on SLT?</i>	124
Yes	89 (71.8)
No	35 (28.2)
<i>What is your most preferred location for 180-degree SLT?</i>	81
Superior	10 (12.3)
Inferior	58 (71.6)
Nasal	3 (3.7)
Temporal	3 (3.7)
Inferonasal	3 (3.7)
Inferotemporal	0 (0.0)
Superonasal	0 (0.0)
Superotemporal	0 (0.0)
None	4 (4.9)
<i>Do you normally complete treatment within less than 1 year time on the other half?</i>	86
Yes	42 (48.8)
No	44 (51.2)

Of those who repeat SLT on patients ($n = 109$), 88 (80.7%) found repeat SLT treatments have good outcomes for patients.

Impact of Practice Duration and Glaucoma Fellowship on Practice Pattern

There was no association between the length of practice and practice patterns in terms of laser preference (p value = 0.437), treatment algorithm (p value = 0.347), perception of predictors of success (p value = 0.179), or repeatability of SLT (p value = 0.145). Similarly,




Fig. 2: Main predictor of SLT success per respondents. IOP, intraocular pressure; LTP, laser trabeculoplasty

no association was found between glaucoma fellowship training and these factors. However, significantly more comprehensive ophthalmologists desired a practice guideline for LTP (p value <0.001) and perceived they were not up-to-date on recent SLT research (p value = 0.003) compared to glaucoma subspecialists.

DISCUSSION

This study reviews the LTP perception and practice patterns of Canadian ophthalmologists. Of the responding COS members who perform LTP, only a quarter were glaucoma subspecialists. This is in keeping with Campbell et al.'s findings of an increase in the provision of clinic-based glaucoma services, including laser trabeculoplasty, by non-diversified cataract surgeons in Canada.²⁴ Given an increasing role of comprehensive ophthalmologists in glaucoma management and laser treatments, it is important to ensure competencies in these domains are achieved during residency training. This is supported by the fact that 42.7% and 15.3% of the respondents' main influence on LTP practice pattern was from past clinical experience and residency training, respectively. Furthermore, significantly more comprehensive ophthalmologists perceived they were not up to date on recent SLT research (8.6% vs 34.8%, p value = 0.003) and desired LTP practice guidelines (78.9% vs 18.1%, p value <0.001) compared to glaucoma subspecialists. This may suggest the need for dedicated continuing medical education resources^{25,26} and best practice guidelines, including recommendations on treatment algorithms and laser settings, for non-glaucoma specialists.

In terms of practice, our study confirms^{27–29} that ALT was largely replaced with SLT upon its introduction. The most significant reason (30.7%) was that SLT causes less trabecular meshwork damage. Reasons following were repeatability (16.2%) and availability (16.2%). Of the very few respondents ($n = 4$), who continue to use ALT in their practice, the main reason was availability. Our study demonstrates that laser availability influences LTP practice patterns of Canadian ophthalmologists. No previous comparative studies were found on the availability and access to LTP. Although ALT and SLT have similar efficacies in lowering IOP, SLT has been suggested to be more safe and repeatable.^{30–32} Given the high technological turnover in ophthalmology, there is a need to ensure new treatment modalities with proven benefits are accessible to all patients.

Only 17.7% of responding ophthalmologists used LTP as a first-line therapy. SLT has been shown to have comparable efficacy and success rate as primary medical monotherapy.^{33–36} Recently, the LiGHT trial showed SLT treatment group, when compared to medical treatment group, maintained target IOP (93.0% vs 91.3%) at more visits, and required less surgical management (0 vs 11 patients) in a 36 month period.³⁷ SLT was also found to be more cost effective compared to medications.³⁷ The study recommended that SLT should be offered as first-line treatment for OAG and ocular hypertension.³⁷ Lee and Hutnik also demonstrated that the use of primary SLT over mono-, bi-, and tri-drug treatment produced a 6 year cumulative cost saving of \$580.52, \$2042.54, and \$3366.65 per patient in the Ontario Health Insurance Plan, respectively.³⁸

Furthermore, SLT has low complication rates³¹ and may help reduce occurrence of ocular surface disorders in chronic glaucoma medication users. Schwartz and Quigley found at 1 year persistence with glaucoma medications tended to be less than 50%.³⁹ Ocular surface disorders caused by glaucoma medications has been associated with poorer glaucoma-related quality of life in patients.^{40,41} Furthermore, lack of adherence to glaucoma medications has been associated with worse prognosis.^{42,43} Thus, SLT may be a method to improve treatment adherence and patient quality of life by minimizing the number of topical medications.⁴⁴ The relatively small percentage of ophthalmologists using LTP as first-line therapy may be related to the ophthalmologist's awareness and perception of LTP effects, patient's disease status, patient's perception and fear of laser surgery, and the irreversible nature of LTP compared to topical medications. Nevertheless, as more evidence surfaces on LTP as initial therapy to glaucoma, there may be a future shift in paradigm for earlier use of LTP in appropriate patients.

In terms of technique, 180-degree SLT was by far the most preferred method (69.9%). Studies have found 180- and 360-degree SLT to be comparable in efficacy of lowering IOP.^{33,45,46} However, Prasad et al. found that 360-degree SLT achieves smaller IOP fluctuation than 180-degree SLT.⁴⁷ In all, 90-degree SLT was shown to have inferior outcome compared to 180- and 360-degree SLT,³³ and only two ophthalmologists in our study selected 90-degree SLT as their preferred practice. Of those who perform 180-degree SLT, 48.8% stated they perform laser on the other half within 1 year. The reason for completion of the other half was not collected; however, it is likely related to suboptimal IOP reduction after initial treatment and treatment preference. There may also be financial incentives for ophthalmologists to perform two 180-degree SLT as opposed to one 360-degree SLT.

For postoperative care, 58.9% of respondents used either topical steroid or NSAID drops. Two randomized clinical trials have demonstrated thus far that such anti-inflammatory medications do not cause a significant difference in pain, redness, anterior chamber reaction, or post-treatment IOP spike after 180- and 360-degree SLT.^{48,49} Future studies that demonstrate consistent results as these RCTs may warrant practice changes that make postoperative care for SLT less burdensome for patients.

SLT tends to wane in efficacy with time. In Juzych et al.'s retrospective study, success rate of 180-degree SLT was 68% at 1 year, 46% at 3 years, and 32% at 5 years after treatment.¹⁸ In Lai et al.'s prospective randomized controlled trial, 27.6% of participants treated with SLT required additional treatment at 5 year follow-up.⁵⁰ Thus, many patients may benefit from repeat SLT in their lifetime. Our results show that majority ($n = 109$) of responding

ophthalmologists repeat SLT, and 80.7% of those who repeat find it efficacious. Retrospective studies to date have shown that there is a significant IOP reduction from baseline following repeat SLT; however, magnitude is less than that of initial SLT.^{17,51–53} Despite limited evidence, 46.0% of the responding ophthalmologists stated they repeat SLT more than one time. Likely explanation for such practices may include patient's preference, avoidance of surgery, intolerance to medications, and need for IOP stability, among others. Further studies are required to determine the efficacy and rationale for such practice. Additionally, although 68.3% of the respondents stated they are more likely to repeat SLT on patients with previous SLT than ALT, Birt's study demonstrated that there is no significant difference in mean IOP reduction at 1 year between these two groups.¹³

This study provides novel information on practice patterns and perceptions of ophthalmologists performing LTP that are not available from studies conducted through OHIP or Medicare databases. Our response rate was adequate and comparable to other internet-based and subspecialist surveys. Limitations to this study include those inherent to the design, such as low response rate and recall bias. However, our response rate of 33% align with published surveys in the literature. Furthermore, most of the questions were in multiple-choice format which limited the response to the choices provided. The study was also limited to the survey length and provides a superficial overview of LTP practice patterns. For instance, this survey did not explore other LTP modalities, such as, micropulse laser trabeculoplasty and titanium-sapphire laser trabeculoplasty. Future studies may benefit from exploring how practice is altering with introduction of these newer modalities.

CONCLUSION

To the best of our knowledge, this is the first study to evaluate the LTP practice patterns and perceptions of Canadian ophthalmologists. Our results show high concordance between Canadian ophthalmologists in well studied areas of LTP; however, in the more controversial areas, there is variability. This survey provides a baseline to which future trends in glaucoma laser treatment can be compared, as new evidence and laser modalities arise.

MEETING PRESENTATION

Poster Presentation at 2019 COS annual meeting.

REFERENCES

1. Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. *Lancet Global Health* 2013;1(6):e339–e349. DOI: 10.1016/S2214-109X(13)70113-X.
2. Quigley HA. Number of people with glaucoma worldwide. *Br J Ophthalmol* 1996;80(5):389–393. DOI: 10.1136/bjo.80.5.389.
3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* 2006;90(3):262–267. DOI: 10.1136/bjo.2005.081224.
4. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013.
5. Latina MA, de Leon JM. Selective laser trabeculoplasty. *Ophthalmol Clin North Am* 2005;18(3):409–419. DOI: 10.1016/j.ohc.2005.05.005.
6. Latina MA, Park C. Selective targeting of trabecular meshwork cells: *in vitro* studies of pulsed and cw laser interactions. *Exp Eye Res* 1995;60(4):359–371. DOI: 10.1016/S0014-4835(05)80093-4.

7. Agarwal HC, Sihota R, Das C, et al. Role of argon laser trabeculoplasty as primary and secondary therapy in open angle glaucoma in indian patients. *Br J Ophthalmol* 2002;86(7):733–736. DOI: 10.1136/bjo.86.7.733.
8. Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. *Arch Ophthalmol* 1979;97(2):319–322. DOI: 10.1001/archophth.1979.01020010165017.
9. Bovell AM, Damji KF, Hodge WG, et al. Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty? *Can J Ophthalmol* 2011;46(5):408–413. DOI: 10.1016/j.jcjo.2011.07.016.
10. Damji KF, Bovell AM, Hodge WG, et al. Selective laser trabeculoplasty vs argon laser trabeculoplasty: results from a 1 year randomised clinical trial. *Br J Ophthalmol* 2006;90(12):1490–1494. DOI: 10.1136/bjo.2006.098855.
11. Damji KF, Shah KC, Rock WJ, et al. Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. *Br J Ophthalmol* 1999;83(6):718–722. DOI: 10.1136/bjo.83.6.718.
12. Pham H, Mansberger S, Brandt JD, et al. Argon laser trabeculoplasty vs selective laser trabeculoplasty. *Surv Ophthalmol* 2008;53(6):641–646. DOI: 10.1016/j.survophthal.2008.08.020.
13. Birt CM. Selective laser trabeculoplasty retreatment after prior argon laser trabeculoplasty: 1 year results. *Can J Ophthalmol* 2007;42(5):715–719. DOI: 10.3129/i07-131.
14. Russo V, Barone A, Cosma A, et al. Selective laser trabeculoplasty vs argon laser trabeculoplasty in patients with uncontrolled open-angle glaucoma. *Eur J Ophthalmol* 2009;19(3):429–434. DOI: 10.1177/112067210901900317.
15. Rosenfeld E, Shemesh G, Kurtz S. The efficacy of selective laser trabeculoplasty vs argon laser trabeculoplasty in pseudophakic glaucoma patients. *Clin Ophthalmol* 2012;6:1935–1940. DOI: 10.2147/OPHT.S34193.
16. Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, et al. Selective vs argon laser trabeculoplasty: hypotensive efficacy, anterior chamber inflammation, and postoperative pain. *Eye (Lond)* 2004;18(5):498–502. DOI: 10.1038/sj.eye.6700695.
17. Hutnik C, Crichton A, Ford B, et al. Selective laser trabeculoplasty vs argon laser trabeculoplasty in glaucoma patients treated Previously with 360 degrees selective laser trabeculoplasty: a randomized, single-blind, equivalence clinical trial. *Ophthalmology* 2018;126(2):223–232. DOI: 10.1016/j.ophtha.2018.09.037.
18. Juzych MS, Chopra V, Banitt MR, et al. Comparison of long-term outcomes of selective laser trabeculoplasty vs argon laser trabeculoplasty in open-angle glaucoma. *Ophthalmology* 2004;111(10):1853–1859. DOI: 10.1016/j.ophtha.2004.04.030.
19. Kent SS, Hutnik CM, Birt CM, et al. A randomized clinical trial of selective laser trabeculoplasty vs argon laser trabeculoplasty in patients with pseudoexfoliation. *J Glaucoma* 2015;24(5):344–347. DOI: 10.1097/IJG.0b013e31829e55e4.
20. Song JSA, Vianna J, Shuba L, et al. Evaluating selective laser trabeculoplasty vs argon laser trabeculoplasty in pseudoexfoliation glaucoma patients. *Can J Ophthalmol* 2018;53(1):70–75. DOI: 10.1016/j.jcjo.2017.07.004.
21. Wang H, Cheng JW, Wei RL, et al. Meta-analysis of selective laser trabeculoplasty with argon laser trabeculoplasty in the treatment of open-angle glaucoma. *Can J Ophthalmol* 2013;48(3):186–192. DOI: 10.1016/j.jcjo.2013.01.001.
22. Wang W, He M, Zhou M, et al. Selective laser trabeculoplasty vs argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis. *PLoS One* 2013;8(12):e84270. DOI: 10.1371/journal.pone.0084270.
23. Zhao JC, Grosskreutz CL, Pasquale LR. Argon vs selective laser trabeculoplasty in the treatment of open angle glaucoma. *Int Ophthalmol Clin* 2005;45(4):97–106. DOI: 10.1097/01.iio.0000176370.01511.6e.
24. Campbell RJ, Bell CM, Gill SS, et al. Clinic-based glaucoma care in the era of surgical subspecialization. *Am J Ophthalmol* 2014;157(3):631–9. e1-2. DOI: 10.1016/j.ajo.2013.11.019.
25. Prum Jr. BE, Lim MC, Mansberger SL, et al. Primary open-angle glaucoma suspect preferred practice pattern((R)) guidelines. *Ophthalmology* 2016;123(1):P112–P151. DOI: 10.1016/j.ophtha.2015.10.055.
26. Prum Jr. BE, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern((R)) guidelines. *Ophthalmology* 2016;123(1):P41–P111. DOI: 10.1016/j.ophtha.2015.10.053.
27. Szigiato AA, Trope GE, Jin Y, et al. Trends in glaucoma surgical procedures in Ontario: 1992–2012. *Can J Ophthalmol* 2015;50(5):338–344. DOI: 10.1016/j.jcjo.2015.07.005.
28. Rachmiel R, Trope GE, Chipman ML, et al. Laser trabeculoplasty trends with the introduction of new medical treatments and selective laser trabeculoplasty. *J Glaucoma* 2006;15(4):306–309. DOI: 10.1097/01.ijg.0000212233.11287.b3.
29. Arora KS, Robin AL, Corcoran KJ, et al. Use of various glaucoma surgeries and procedures in medicare beneficiaries from 1994 to 2012. *Ophthalmology* 2015;122(8):1615–1624. DOI: 10.1016/j.ophtha.2015.04.015.
30. Rolim de Moura C, Paranhos Jr. A, Wormald R. Laser trabeculoplasty for open angle glaucoma. *Cochrane Database Syst Rev* 2007;4:CD003919. DOI: 10.1002/14651858.CD003919.p02.
31. Leahy KE, White AJ. Selective laser trabeculoplasty: current perspectives. *Clin Ophthalmol* 2015;9:833–841. DOI: 10.2147/OPHT.S53490.
32. McAlinden C. Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review. *Eye (Lond)* 2014;28(3):249–258. DOI: 10.1038/eye.2013.267.
33. Nagar M, Ogunyomade A, O'Brart DP, et al. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. *Br J Ophthalmol* 2005;89(11):1413–1417. DOI: 10.1136/bjo.2004.052795.
34. McIlraith I, Strasfeld M, Colev G, et al. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. *J Glaucoma* 2006;15(2):124–130. DOI: 10.1097/00061198-200604000-00009.
35. Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study. *Arch Ophthalmol* 2003;121(7):957–960. DOI: 10.1001/archophth.121.7.957.
36. Katz LJ, Steinmann WC, Kabir A, et al. Selective laser trabeculoplasty vs medical therapy as initial treatment of glaucoma: a prospective, randomized trial. *J Glaucoma* 2012;21(7):460–468. DOI: 10.1097/IJG.0b013e318218287f.
37. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty vs eye drops for first-line treatment of ocular hypertension and glaucoma (light): a multicentre randomised controlled trial. *Lancet* 2019;393(10180):1505–1516. DOI: 10.1016/S0140-6736(18)32213-X.
38. Lee R, Hutnik CM. Projected cost comparison of selective laser trabeculoplasty vs glaucoma medication in the Ontario health insurance plan. *Can J Ophthalmol* 2006;41(4):449–456. DOI: 10.1016/S0008-4182(06)80006-2.
39. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. *Surv Ophthalmol* 2008;53(Suppl 1):S57–S68. DOI: 10.1016/j.survophthal.2008.08.002.
40. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. *J Glaucoma* 2008;17(5):350–355. DOI: 10.1097/IJG.0b013e31815c5f4f.
41. Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. *Am J Ophthalmol* 2012;153(1):1–9.e2. DOI: 10.1016/j.ajo.2011.05.033.
42. Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. *Ophthalmology* 2011;118(12):2398–2402. DOI: 10.1016/j.ophtha.2011.05.013.
43. Friedman DS, Okeke CO, Jampel HD, et al. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. *Ophthalmology* 2009;116(6):1097–1105. DOI: 10.1016/j.ophtha.2009.01.021.

44. Stein JD, Kim DD, Peck WW, et al. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. *Arch Ophthalmol* 2012;130(4): 497–505. DOI: 10.1001/archophthalmol.2011.2727.
45. Woo DM, Healey PR, Graham SL, et al. Intraocular pressure-lowering medications and long-term outcomes of selective laser trabeculoplasty. *Clin Exp Ophthalmol* 2015;43(4):320–327. DOI: 10.1111/ceo.12452.
46. Goyal S, Beltran-Agullo L, Rashid S, et al. Effect of primary selective laser trabeculoplasty on tonographic outflow facility: a randomised clinical trial. *Br J Ophthalmol* 2010;94(11):1443–1447. DOI: 10.1136/bjo.2009.176024.
47. Prasad N, Murthy S, Dagianis JJ, et al. A comparison of the intervisit intraocular pressure fluctuation after 180 and 360 degrees of selective laser trabeculoplasty (SLT) as a primary therapy in primary open angle glaucoma and ocular hypertension. *J Glaucoma* 2009;18(2):157–160. DOI: 10.1097/IJG.0b013e3181752c97.
48. Jinapriya D, D'Souza M, Hollands H, et al. Anti-inflammatory therapy after selective laser trabeculoplasty: a randomized, double-masked, placebo-controlled clinical trial. *Ophthalmology* 2014;121(12):2356–2361. DOI: 10.1016/j.ophtha.2014.07.017.
49. De Keyser M, De Belder M, De Groot V. Randomized prospective study of the use of anti-inflammatory drops after selective laser trabeculoplasty. *J Glaucoma* 2017;26(2):e22–e29. DOI: 10.1097/IJG.0000000000000522.
50. Lai JS, Chua JK, Tham CC, et al. Five-year follow up of selective laser trabeculoplasty in Chinese eyes. *Clin Exp Ophthalmol* 2004;32(4): 368–372. DOI: 10.1111/j.1442-9071.2004.00839.x.
51. Khouri AS, Lari HB, Berezina TL, et al. Long term efficacy of repeat selective laser trabeculoplasty. *J Ophthalmic Vis Res* 2014;9(4): 444–448. DOI: 10.4103/2008-322X.150814.
52. Polat J, Grantham L, Mitchell K, et al. Repeatability of selective laser trabeculoplasty. *Br J Ophthalmol* 2016;100(10):1437–1441. DOI: 10.1136/bjophthalmol-2015-307486.
53. Francis BA, Loewen N, Hong B, et al. Repeatability of selective laser trabeculoplasty for open-angle glaucoma. *BMC Ophthalmol* 2016;16:128. DOI: 10.1186/s12886-016-0299-9.